Meeting
2023 ASCO Genitourinary Cancers Symposium
Efficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
Authors
Rabbia Siddiqi
University of Toledo, Toledo, OH
Rabbia Siddiqi , Gaurav Kumar , Hafsah Ijaz , Syed Arsalan Ahmed Naqvi , Ahsan Ayaz , Zaryab Bin Riaz , Alan Haruo Bryce , Thai Huu Ho , Irbaz Bin Riaz , Parminder Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 692)
DOI
10.1200/JCO.2023.41.6_suppl.692
Abstract #
692
Poster Bd #
J5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.
First Author: Yu Fujiwara
Poster
2024 ASCO Genitourinary Cancers Symposium
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
First Author: Regina Barragan-Carrillo
Poster
2024 ASCO Genitourinary Cancers Symposium
Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis.
First Author: Oluseyi Abidoye
Poster
2022 ASCO Annual Meeting
A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.
First Author: Giuseppe Viscardi